This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss the correct way to diagnose primary aldosteronism. Is a spot ARR sufficient? Prepare to turn whatever you thought you knew about PA around.
The opioid epidemic is tragically providing a lot of organs for transplant. We are using more over-dose death organs than ever before. Do they measure up?